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CD44 is a direct target of  
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Osteosarcoma is the most common primary bone malignancy in children and adolescents. 
Herein, we investigated the role of cluster of differentiation 44 (CD44), a cell-surface glycoprotein 
involved in cell-cell interactions, cell adhesion, and migration in osteosarcoma. We constructed 
a human osteosarcoma tissue microarray with 114 patient tumor specimens, including tumor 
tissues from primary, metastatic, and recurrent stages, and determined the expression of CD44 by 
immunohistochemistry. Results showed that CD44 was overexpressed in metastatic and recurrent 
osteosarcoma as compared with primary tumors. Higher expression of CD44 was found in both 
patients with shorter survival and patients who exhibited unfavorable response to chemotherapy 
before surgical resection. Additionally, the 3′-untranslated region of CD44 mRNA was the direct 
target of microRNA-199a-3p (miR-199a-3p). Overexpression of miR-199a-3p significantly inhibited 
CD44 expression in osteosarcoma cells. miR-199a-3p is one of the most dramatically decreased miRs 
in osteosarcoma cells and tumor tissues as compared with normal osteoblast cells. Transfection 
of miR-199a-3p significantly increased the drug sensitivity through down-regulation of CD44 in 
osteosarcoma cells. Taken together, these results suggest that the CD44-miR-199a-3p axis plays an 
important role in the development of metastasis, recurrence, and drug resistance of osteosarcoma. 
Developing strategies to target CD44 may improve the clinical outcome of osteosarcoma.
Osteosarcoma is an aggressive primary sarcoma of bone, and is the eighth-most common form of child-
hood malignancy1,2. The 5-year survival for patients with localized osteosarcoma remains at 60–70% 
with multi-agent chemotherapy treatment together with surgical techniques3. Up to 20–25% of patients 
may have detectable metastatic disease at the time of diagnosis4. Metastatic osteosarcoma usually has 
unsatisfactory rates of response to the current standard chemotherapy, resulting in poor prognosis. The 
5-year survival rate for patients with aggressive metastases is only 10–30%5. So far, the mechanisms 
controlling the aggressiveness of osteosarcoma have not been clearly characterized. The cellular and 
molecular mechanisms underlying metastasis formation and the development of chemoresistance in 
osteosarcoma remain unclear6.
High expression of some specific cell surface proteins has been found to contribute to tumor ini-
tiation, progression, and poor clinical outcome. Among these proteins, cluster of differentiation 44 
(CD44) is a receptor for hyaluronic acid (HA) and can interact with other ligands, such as osteopontin, 
collagens, and matrix metalloproteinases (MMPs). The binding of different ligands to CD44 triggers 
direct cross-signaling between different signaling pathways, including HER2, Src kinase, and ERK7. 
1Sarcoma Biology Laboratory, Center for Sarcoma and Connective Tissue Oncology, Massachusetts General 
Hospital and Harvard Medical School, Boston, MA 02114. 2Department of Clinical Laboratory, The Third Affiliated 
Hospital of Zhengzhou University, Zhengzhou 450052, Henan Province, China. Correspondence and requests for 
materials should be addressed to Z.D. (email: zduan@mgh.harvard.edu)
received: 19 January 2015
Accepted: 22 May 2015
Published: 16 June 2015
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 5:11365 | DOi: 10.1038/srep11365
Overexpression of CD44 enhances tumor cell growth, cancer stem cell differentiation, chemoresistance, 
and metastases7,8. Mice with disruption of the CD44 gene showed virtually ablated metastasis formation 
in osteosarcoma9. The CD44-HA interaction has been found to enhance lung metastasis and chemore-
sistance in osteosarcoma cells10. Lung metastasis of osteosarcoma can be accelerated by upregulation of 
CD44 in vivo in mouse models11. However, few reports have studied the role of CD44 in a larger number 
of osteosarcoma patients with well-established clinical information.
MicroRNAs (miRNAs, miRs) play critical roles in the regulation of genes involved in controlling 
tumor pathogenesis and progression. miRs bind to the 3′ -untranslated region (3′ -UTR) of specific gene 
mRNAs and participate in the regulation of many biological functions in tumor cells12. Several reports 
also demonstrated that CD44 is the direct target of miR-34 and miR-32813,14. In addition, we have pre-
viously identified miR-199a-3p as a significantly decreased miR in osteosarcoma15. In the current study, 
we evaluated the role of CD44 in osteosarcoma progression and also identified that miR-199a-3p could 
modulate the drug sensitivity of osteosarcoma through targeting CD44.
Results
CD44 is overexpressed in osteosarcoma cell lines and metastatic/recurrent osteosarcoma 
tissues. We examined the relative protein levels of CD44 in osteoblast and osteosarcoma cell lines. 
There was modest expression of CD44 in HOB-c and minimal expression of CD44 in NHOst osteoblast 
cell lines. However, KHOS and U-2OS exhibited significantly higher expression of CD44 (P = 0.0137, 
Fig. 1A). To confirm these cell lines data in primary tumor tissues, eight primary osteosarcoma specimens 
Figure 1. Expression of CD44 in osteosarcoma tissues, osteosarcoma/osteoblast cell lines, and its 
clinical significance. A expression levels of CD44 in osteoblast and osteosarcoma cell lines were assessed 
by western blot. B expression levels of CD44 in eight osteosarcoma tissue specimens was determined by 
western blot. C distribution of CD44 immunohistochemical staining scores in primary, metastatic, and 
recurrent osteosarcoma tissues. D comparison of CD44 immunostaining density between good response 
and poor response osteosarcoma tissues based on the histological necrosis percentage after pre-operation 
chemotherapy. E correlation between expression of CD44 (CD44 staining ≤ 1+ and CD44 staining ≥ 2+ ) 
and overall survival in osteosarcoma patients. F representative pictures of CD44 expression in osteosarcoma 
tissues.
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were also examined by Western blot analysis to exclude the possibility of CD44 expression being an 
artifact induced by in vitro culture. Different levels of CD44 expression were once again observed in 
these osteosarcoma patient samples, indicating endogenous expression of CD44 in tumor cells. (Fig. 1B). 
Subsequently, we performed immunohistochemistry to evaluate the significance of CD44 in a large num-
ber of osteosarcoma patients. The TMA used in this study consisted of 14 biopsy samples (considered as 
primary samples without pre-operative chemotherapy), 56 primary samples, 35 metastatic samples and 
nine recurrent samples. In total, 114 paraffin blocks were selected to build the TMA. Consistent with the 
tissue western blot result (Fig. 1B), osteosarcoma specimens presented various degrees of CD44 expres-
sion staining on the cell membrane (Fig.  1F). The expression levels of CD44 were significantly higher 
in metastatic tumors than in primary osteosarcoma tissues (P value of metastatic vs. primary < 0.0001, 
Fig. 1C). There was a tendency for increased CD44 expression in recurrent osteosarcoma (Fig. 1C); how-
ever, no significant difference was observed between recurrent and primary samples (P value of recurrent 
vs. primary = 0.308). These results may reflect the small number of cases of recurrent specimens in the 
TMA. There were only six samples applicable for immunostaining analysis due to detachment during 
the experimental procedures.
Upregulation of CD44 is correlated with poor chemotherapy response and unfavorable clin-
ical outcome. To investigate the clinical relevance between CD44 expression and osteosarcoma, we 
analyzed the relation of CD44 expression with osteosarcoma progression and prognosis. Among the 114 
tissues selected in this TMA, 77 tissues were treated with chemotherapeutic drugs before undergoing 
surgery. The proportion of histological necrosis in tumors was carefully evaluated after surgical resection. 
Previous reports have shown that in the treatment of osteosarcoma, a good response is defined as more 
than 90% necrosis in the excised tumor, and poor response with the criteria is less than 90% histological 
necrosis16. In the specimens of this TMA, nine patients showed good response, while 47 tissues presented 
poor response to chemotherapy, and 21 tumor samples were not applicable for determining necrosis 
(Table 1). The data showed poor response osteosarcoma patients demonstrated a significantly higher level 
of CD44 expression, in comparison with good response counterparts (P value of good response vs. poor 
response = 0.0484, Fig. 1D, Table 1).
To further prove the clinical significance of CD44 expression in patients with osteosarcoma, the TMA 
specimen clinical information, including follow-up months, was collected (Table  2 and Table S1). The 
longest follow-up of a living patient is 255 months. The results showed that shorter overall survival was 
correlated with stronger expression of CD44. In the Kaplan-Meier survival analysis, CD44 expression 
scores were subgrouped into two categories: weak CD44 staining with score ranging from 0 to 1+ , and 
strong CD44 staining with score ranging from 2+ to 3+ . The survival analysis indicated that the out-
come for patients in the CD44 strong-staining group was significantly worse than for those in the CD44 
weak-staining group (P = 0.0448, Fig. 1E).
CD44 is a direct target of miR-199a-3p in osteosarcoma. To identify the specific miR that plays 
significant roles in cellular motility, adhesion, and invasion in osteosarcoma through targeting CD44, 
we employed a number of widely used computational analysis databases, including microRNA.org and 
TargetScan databases, to search for putative binding sites of some miRs in the 3′ -UTR of human CD44 
gene mRNA. One of the top ranked and highest scoring miRs was miR-199a-3p. Further analysis showed 
that the alignment of predicted miR-199a-3p target sequences in CD44 mRNA reside at nucleotide 74 to 
91 from the start of the CD44 3′ -UTR (Fig. 2A). Therefore, miR-199a-3p could be a potential regulator of 
CD44 expression. Importantly, our previous study has demonstrated that the expression of miR-199a-3p 
was dramatically decreased in osteosarcoma cell lines (U-2OS and KHOS) in comparison with normal 
osteoblast (HOB-c and NHOst) cells (Fig. 2B)15.
In order to evaluate whether CD44 is a direct target of miR-199a-3p, osteosarcoma cell lines U-2OS 
and KHOS were transfected with miR-199a-3p mimic, and the effects on CD44 expression were deter-
mined. As revealed by Western blot analysis, levels of CD44 were significantly suppressed in the cells 
treated with miR-199a-3p in a dose-dependent manner (Fig.  3A,B). Specifically, when normalized to 
control cells, the expression levels of CD44 in cells transfected with 10 nM, 20 nM, and 40 nM miR-
199a-3p mimic were decreased to 80.4%, 53.3%, 29.2%, and 18.3% for U-2OS, and 75.5%, 68.7%, 39.2%, 
and 43.1% for KHOS. In addition, protein from U-2OS dosed with 60 nM miR-199a-3p was collected 
Good response* 
(% pre-operative 
chemotherapy)
Poor response* 
(% pre-operative 
chemotherapy)
N/A* (% pre-
operative 
chemotherapy)
CD44 High staining 2 (22.2%) 25 (53.2%) 18 (85.7%) 
CD44 Weak staining 7(77.8%) 22 (46.8%) 3 (14.3%)
Total 9 47 21
Table 1. Histological response to pre-operative chemotherapy and CD44 immunostaining. *Good 
response: ≥ 90% necrosis; Poor response: <90% necrosis; N/A: not applicable.
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at different time points to determine the time-dependent knockdown effect of CD44. CD44 expression 
was decreased by 51.0%, 66.7%, and 75.8% at 24 h, 48 h, and 72 h, respectively. These results suggested 
that miR-199a-3p repressed CD44 expression in both a dose-dependent and time-dependent manner.
miR-199a-3p transfection increased drug sensitivity by knocking down CD44 in osteosar-
coma. Expression of CD44 has been found to be associated with chemoresistance and recurrence 
during cancer metastasis and progression. Dysregulation of miRs has also been associated with drug 
resistance in different tumors. To examine whether repression of CD44 levels by miR-199a-3p would 
increase drug sensitivity of osteosarcoma cells, the MTT assay was performed on our previously estab-
lished cell lines U-2OS/null and U-2OS/miR-199a-3p after incubating with doxorubicin. Transfection 
of miR-199a-3p significantly restored the sensitivity to chemotherapeutic drug doxorubicin in U-2OS. 
Considering the clinical data we obtained that osteosarcoma patients who responded poorly to chemo-
therapy presented stronger CD44 levels, it is hypothesized that miR-199a-3p may attenuate drug resist-
ance through inhibition of CD44 expression.
Characteristic
Follow up period Average (range), 
months 80.96 (0–255)
Age at diagnosis Average (range), years 30.55 (6–77)
 >40 28
 <=40 86
Gender
 Male 73
 Female 41
Treatment status
 Pre-operative chemotherapy ( % ) 77 (67.5%)
 No pre-operative chemotherapy ( % ) 37 (32.5%)
Stages
 Primary 70
 Metastatic 35
 Recurrent* 9
Table 2. Characteristics of the study osteosarcoma patients. *There were only 6 samples applicable for 
immunostaining analysis due to the detachment during experimental procedures.
Figure 2. CD44 is a direct target of miR-199a-3p, and the miR-199a-3p expression profile in osteoblast 
and osteosarcoma cell lines. A Alignment of the predicted miR-199a-3p 3′ -UTR target sequences of CD44 
mRNA. The seed match sequences for miR-199a-3p are indicated by lines. B comparison of miR-199a-3p 
expression levels between in comparison with osteoblasts (HOB-c and NHOst) and osteosarcoma cells  
(U-2OS and KHOS) based on the miR microarray platform and unsupervised hierarchical clustering analysis.
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Discussion
Our current study indicated that upregulation of CD44 is correlated with aggressive behaviors during 
osteosarcoma progression, including metastasis, recurrence, poor response to chemotherapy, as well as 
unfavorable prognosis. We demonstrated that CD44 is a direct target of miR-199a-3p in osteosarcoma. 
miR-199a-3p may mediate the expression level of CD44 and thus impact the drug sensitivity of osteo-
sarcoma cells. These data suggest that the CD44-miR-199a-3p axis may be involved in the development 
of osteosarcoma.
CD44 functions in cell-matrix interactions, cell motility, matrix degradation, as well as proliferation7. 
CD44 expression is up-regulated in high-grade human breast tumors, and causally contributes to the 
epithelial-mesenchymal transition and breast cancer progression17. CD44 also induces attributes of cells 
that have undergone an epithelial-mesenchymal transition, leading to tumor metastasis, and resulting 
in a worse prognosis for colon cancer18. CD44 is highly overexpressed in metastatic ovarian cancer 
cells than in cells isolated from primary tumors19,20. Moreover, knocking down CD44 by its specific 
esiRNA dramatically suppressed the migratory potentials and invasive ability of ovarian cancer cell lines 
in our recent work21. The CD44-HA interaction was shown to enhance lung metastasis in osteosarcoma 
cells10. Based on previous in vivo investigations, mice with disruption of the CD44 gene showed ablated 
metastasis formation in osteosarcoma9. Additionally, upregulation of CD44 accelerated lung metastasis 
in mouse osteosarcoma models11. In line with these reports, we again confirmed that overexpression of 
CD44 protein was exhibited in aggressive osteosarcoma cell lines compared with normal osteoblasts. 
Moreover, we also showed that human osteosarcoma tissues across large sample numbers deriving from 
late stages (metastatic and recurrent stages) have higher CD44 protein expression than tumor samples in 
the primary stage. Therefore, CD44 may indeed be a critical modulator in the metastatic and recurrent 
progression of osteosarcoma.
Figure 3. The dose and time dependent effect of miR-199a-3p on knocking down CD44 and increasing 
the doxorubicin sensitivity of osteosarcoma. A and B miR-199a-3p knocked down CD44 in osteosarcoma 
cells as a dose dependent manner. C and D miR-199a-3p knocked down CD44 in osteosarcoma cells as a 
time dependent manner. E MTT assay showing cell viability of U-2OS, U-2OS/miR-null, and U-2OS/miR-
199a-3p after incubating with different concentrations of doxorubicin.
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Currently, one of the most reproducible prognostic indicators for osteosarcoma patients is histo-
logical necrosis of tumor tissues to preoperative chemotherapy22. A low percentage of necrosis in tum-
ors denotes poor response to chemotherapy and will frequently result in failure of treatment23. Our 
results showed that poor response osteosarcoma patients with less necrotic tumor demonstrated a sig-
nificantly higher level of CD44 expression, in comparison with good response patients with a high per-
centage of necrotic tumors. As we reported recently, stable knocking down CD44 by lentivirus-based 
CD44 shRNA could increase sensitivity to paclitaxel in ovarian cancer cells21. CD44 has been reported 
to be as an anti-apoptotic factor through upregulation of Bcl-xL in doxorubicin resistant breast can-
cer24. Overexpression of CD44 has also been shown to potentiate resistance to etoposide by alteration of 
caspase 9, caspase 3, Bcl-xl, Bak, pRB, and phosphorylation of AKT in colon cancer25. Osteosarcoma is 
still characterized by the development of drug resistance to chemotherapy in late stages26. Although the 
molecular mechanisms elucidating osteosarcoma chemoresistance remains unknown, CD44 may play a 
pivotal part in chemoresistance on the basis of our analysis in clinical osteosarcoma tissues.
Association of CD44 expression and clinical prognosis of patients has been studied in diverse malig-
nant tumors, such as colon and breast cancer. Our and others’ previous work have demonstrated that 
ovarian cancer patients with CD44 positive tumors have a significantly shorter disease free survival than 
patients with CD44 negative tumors21,27,28. However, the prognostic value of CD44 in osteosarcoma has 
remained largely unknown. Although overexpression of CD44 was indicated as an important prognostic 
parameter in 39 patients with osteosarcoma in a previous study, another group showed that CD44 immu-
noexpression could not predict the prognosis for 34 osteosarcoma patients17,29. Significant correlation 
between CD44 expression and overall survival was not observed within 53 osteosarcoma subjects in a 
recent report10. This controversial data may be largely due to the limited number of cases or incomplete 
clinical information. Notably, the TMA utilized in our current study consisted of a large number of 
osteosarcoma tissues and more complete clinical information. The TMA analysis revealed a significant 
correlation between stronger CD44 expression in surgical osteosarcoma specimens with shorter overall 
survival.
Investigations on miRs have unveiled a novel mechanism of post-transcriptional modification of 
some specific genes that are greatly dysregulated in malignant cells30. Based on the TMA results, we 
then explored the regulation mechanism of CD44 in osteosarcoma. CD44 is mediated by some miRs 
via binding to its 3′ -UTR region in diverse human diseases; for instance, miR-34a in prostate cancer13, 
miR-328 in gastrointestinal cancer14, and miR-373 and miR-520c in breast cancer31. Recent studies have 
demonstrated that miRs might influence the progression of osteosarcoma via pathways involving CD44, 
such as miR-140 and miR-21532,33. The identification of cancer-specific miRs and their targets is impor-
tant for uncovering their roles in tumor carcinogenesis and development, and may be pivotal for the 
discovery of novel therapeutic targets. miR-199a-3p is proven to be a significantly decreased miR in 
different tumors by our and others’ works, including in osteosarcoma15,34,35. Moreover, transfection of 
miR-199a-3p was reported to reduce the cellular proliferation rate and influence doxorubicin sensitivity 
in liver cancer cells, and decrease osteosarcoma cell growth and migration15,36. As a tumor suppressor 
miR, miR-199a-3p was demonstrated to down-regulate Met, mTOR and AXL oncogenes15,34,37. Here, we 
found that CD44 is also a direct target of miR-199a-3p in osteosarcoma. Our findings are consistent with 
recent reports showing that miR-199a-3p can mediate CD44 expression in hepatocelluar carcinoma and 
ovarian cancer38,39. Moreover, miR-199a-3p inhibits the expression of CD44 in osteosarcoma both in a 
time and dose-dependent manner. In accordance with a former study, down-regulation of CD44 by miR-
199a-3p remarkably increased the chemosensitivity to cisplatin, paclitaxel, and adriamycin in ovarian 
cancer cells39. It is assumed that the enhancement of doxorubicin sensitivity in our study may be induced 
by loss of function of CD44 when miR-199a-3p concentration is enriched inside osteosarcoma cells. It 
is worth mentioning here that significantly decreased osteosarcoma cell proliferation and migration has 
been found by restoration of miR-199a-3p15. Taking the aforementioned functions of CD44 and miR-
199a-3p contributed by our and others’ endeavors into account, we hypothesized that the CD44-miR-
199a-3p axis plays an important role in the development of metastasis, recurrence, and drug resistance 
of osteosarcoma (Fig.  4). Aberrantly expressed miR-199a-3p in osteosarcoma leads to the degradation 
of CD44 mRNA and further generates decreased translation of CD44 protein. Overexpression of CD44 
functions in promoting proliferation, metastasis, and drug resistance during osteosarcoma progression.
In conclusion, findings presented in this study refined our insights into the contributions of CD44 
to tumorigenesis, metastasis, and chemoresistance. Our results also underscore the pivotal role of the 
CD44/miR-199a-3p interaction in determining malignancy in osteosarcoma. Therefore, CD44 may 
become a therapeutic target in osteosarcoma.
Methods
Human osteosarcoma tissues microarray (TMA) construction. The formalin-fixed, 
paraffin-embedded tumor specimens from 114 osteosarcoma tissues were selected for construction of 
TMA in the Tissue Microarray Core at the Dana-Farber/Harvard Cancer Center. Haematoxylin and 
eosin-stained slides from each tissue block were read by a pathologist, together with pathology reports 
to obtain representative triplicate 0.5-mm-diameter core biopsies. Clinical information of all the sub-
jects was collected and managed from the archives, including age, gender, tumor location, tumor stage 
(primary/metastasis/recurrent), whether the patient received pre-operative chemotherapy or not, the 
www.nature.com/scientificreports/
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percentage of necrosis of tumor assessed by a senior consultant pathologist if the patient received chemo-
therapy, the disease status, as well as the follow-up months (Table  1, Table  2 and Supplementary data 
Table S1). Institutional Review Board (IRB) approval was obtained to collect all osteosarcoma samples 
from the Partners Human Research Office. Written informed consent was obtained from all patients 
whose specimens and clinical information were used for this research study. All experimental protocols 
were approved by Massachusetts General Hospital (IRB protocol number: 2007P-002464). The methods 
described in this study were carried out in accordance with the approved guidelines.
Human osteoblast and osteosarcoma cell lines culture. Human osteoblast cell line HOB-c was 
purchased from PromoCell GmbH (Heidelberg, Germany), osteoblast cell line NHOst was purchased 
from Lonza Wallkersville Inc. (Walkersville, MD). Osteoblast cell lines were cultured in osteoblast 
growth medium (PomoCell) with supplement Mix. The human osteosarcoma cell line KHOS was kindly 
provided by Dr. Efstathios Gonos (Institute of Biological Research & Biotechnology, Athens, Greece). 
The human osteosarcoma cell line U-2OS was obtained from the American Type Culture Collection 
(Rockville, Maryland, USA). Osteosarcoma cell lines were cultured in RPMI 1640 (Life Technologies, 
Grand Island, NY) supplemented with 10% fetal bovine serum (FBS) and 1% penicillin/streptomycin 
(Life Technologies, Carlsbad, CA). All cells were incubated in a humidified atmosphere composed of 
5% CO2 and 95% air.
Immunohistochemistry. The expression levels of CD44 were evaluated following the 
Immunohistochemistry Protocol (Cell Signaling Technology, Beverly, MA). In brief, 5-μ m paraffin tissue 
section slides were baked for 1 hour at 60 °C, deparaffinized in xylene three times for 10 minutes each, 
and then transferred through graded ethanol (100%, 95%) for rehydration. After antigen retrieval, 3% 
hydrogen peroxide was applied to quench the endogenous peroxidase for 10 minutes. Following protein 
blocking for 1 hour at room temperature, the slide was incubated with primary antibody (dilution 1:50) 
at 4 °C overnight in a humidified chamber. Subsequently, bound antibody on the array was detected by 
Figure 4. Schematic representation showing CD44-miR-199a-3p axis mediated aggressive behaviors 
in osteosarcoma. The miR-199a-3p can bind the site within the 3′ -UTR of CD44 mRNA, which leads 
to degradation of the bound RNA. Upregulation of miR-199a-3p in osteosarcoma reduces the expression 
of CD44 mRNA and leads to decreased translation of the functional CD44 protein. On the other hand, 
overexpression of CD44 oncoprotein plays critical roles in promoting proliferation, metastasis, and drug 
resistance during osteosarcoma progression.
www.nature.com/scientificreports/
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SignalStain® Boost Detection Reagent (Cell Signaling Technology) and SignalStain® DAB (Cell Signaling 
Technology). To obtain better images and long-term preservation, the section was counterstained with 
hematoxylin QS (Vector Laboratories) and mounted with VectaMount AQ (Vector Laboratories), respec-
tively. The immunostaining intensity of CD44 was assessed independently by two scientists who had no 
knowledge of the clinical information, as follows: 0, no staining; 1+ , weak staining; 2+ , moderate stain-
ing; and 3+ , intense staining. The negative and positive staining controls are shown in Supplementary 
data Figure S1).
Western blot. Protein lysates of the cells and tissues were extracted with 1 × RIPA lysis buffer (Upstate 
Biotechnology, Charlottesville, VA) supplemented with complete protease inhibitor cocktail tablets (Roche 
Applied Science, IN, USA). The protein concentrations were determined by Protein Assay Reagents 
(Bio-Rad, Hercules, USA). Equal amounts of protein were separated by NuPAGE® 4–12% Bis-Tris Gel 
(Life Technologies), transferred onto nitrocellulose membrane (Bio-Rad), and incubated with specific 
primary antibodies CD44 (Cell Signaling, dilution 1:1000) and β-Actin (Sigma-Aldrich, dilution 1:2000) 
at 4 °C overnight. The membranes were further probed with respective secondary antibodies (LI-COR 
Bioscences, Lincoln, NE), and scanned by Odyssey® CLx equipment (LI-COR Bioscences) to detect the 
bands and the density.
miR-199a-3p mimic/precursor transfection. Transfection of synthetic miR-199a-3p mimic 
(Ambion® mirVanaTM miR-199a-3p mimics, TX) into KHOS and U-2OS cells was performed with 
Lipofectamine® RNAiMAX Reagent (Invitrogen) according to the manufacturer’s instructions. A 
non-specific miR mimic (Ambion® mirVanaTM miRNA mimics Negative Control) was used as a nega-
tive control. Forty-eight or 72 hours post-transfection, the proteins were extracted and stored at − 80 °C 
for further study. Transfection of expression vector-based miR-199a-3p precursor and miRNASelect™ 
pEP-miR-Null (Cell Biolab, Inc, San Diego, CA) into U-2OS, and selection of stable clones was per-
formed as previously described15.
Chemotherapy drug sensitivity analysis. The cytotoxicity of anticancer drug doxorubicin to oste-
osarcoma cells were assessed by MTT (3(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide) 
assay. U-2OS, U-2OS/miR-null, and U-2OS/miR-199a-3p cells were seeded into 96-well microplates at a 
density of 1 × 103 cells per well and incubated with a series of concentrations of doxorubicin, which were 
supplied by the pharmacy at the Massachusetts General Hospital. After 5-day exposure to doxorubicin, 
20 μ L MTT (Sigma-Aldrich) was dosed and then incubated for another 4 hours at 37 °C and 5% CO2 
atmosphere. The resulting intracellular formazan crystals was solubilized in acid-isopropanol. Finally, the 
absorbances were assessed on a SpectraMax Microplate® Spectrophotometer (Molecular Devices LLC, 
Sunnyvale, CA) at 490 nm. The MTT assay was conducted in triplicate.
Statistical analysis. The data were analyzed using Prism 5.0 software (Graph Pad Software Inc., 
San Diego, CA), and expressed as mean ± SEM. Statistical significance was assessed using independent 
two-tailed Student t-tests for independent data. Overall survival was analyzed using Kaplan-Meier sur-
vival curves with Log-rank (Mantel-Cox) Test for significance. Differences of P < 0.05 were considered 
significant for all statistical tests.
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